Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralipid for Prevention of Local Anesthetic Toxicity
NCT01602250Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2011
- Primary completion
- Aug 2013
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Intralipid 10% in local anesthetic systemic toxicity (LAST) (4 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Duration of drug infusion (Time to early neurologic signs of toxicity). Started Jan 2011; status: completed.
02
Drugs
Intralipid 10%
03
Conditions
local anesthetic systemic toxicity (LAST)
Beyond the preview
Go deeper on NCT01602250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01602250.